Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up
BLOOD（2023）
关键词
Diffuse large B-cell lymphoma,refractory/relapsing,polatuzumab vedotin,real-world,study,China.
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要